The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy

Don M. Morris, E. George Elias, Mukund S. Didolkar, Sally D. Brown

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The effect of known chemotherapeutic programs in patints with breast cancer who developed metastasis during or after adjuvant chemotherapy with L‐PAM plus 5‐FU (PF) were switched. Thirteen patients failed while receiving adjuvant therapy at 3–22 months from the time therapy started. Three patients failed 6–28 months after 2 year of therapy. Thirteen patients received PF followed by cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) at the time of progression PF. Of these, ten received Adriamycin and vincristine (AV) at the time of progression on CMF. The response to CMF was 7%. No patint responded to AV after progression on CMF. Two of three patients treated with AV after failure on PF did respond, but both for only 6 responsive to further chemotherapy. Sine most patients failed while on adjuvant therapy, this may indicate a poor prognosis regardless of the agents used.

Original languageEnglish (US)
Pages (from-to)154-157
Number of pages4
JournalJournal of Surgical Oncology
Volume29
Issue number3
DOIs
StatePublished - Jul 1985

Keywords

  • Adjuvant
  • breast
  • cancer
  • failure
  • prognosis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy'. Together they form a unique fingerprint.

Cite this